Clinical trials: Retinal Neovascularization
Age Related Macular Degeneration
Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)
Study come to investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence…
- Trial name
- PHP (NCT00692887)
- Testing
- PHP - Preferential Hyperacuity Perimeter (Foresee)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Conjunctivitis, Glaucoma
Feasibility Study and Preliminary Application Study on Iris OCTA
All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.
- Conditions
- Conjunctivitis, Glaucoma, Myopia, Diabetic Retinopathy
- Trial name
- NCT03631108
- Testing
- OCTA (ZEISS)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Angioid Streaks, Choroidal Neovascularization
Intravitreal Bevacizumab in Agioid Streaks
The purpose of this study is to investigate the safety and efficacy of intravitreal bevacizumab in patients with choroidal neovascularization associated with angioid streaks.
- Trial name
- NCT00406250
- Testing
- intravitreal injection
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- University of Campania Luigi Vanvitelli
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular…
- Conditions
- Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
- Trial name
- NCT02599064
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Age Related Macular Degeneration, Choroidal Neovascularization
Sensitivity of the Home Macular Perimeter (HMP)
estimate the sensitivity of the HMP test in identifying visual field functional defects in subjects with CNV secondary to AMD
- Trial name
- HMP (NCT00604071)
- Where
- 10 sites in United States
- Volunteers
- 99 people
- Sponsor
- Notal Vision Ltd.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique using a dual blade speculum among patients…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion With Macular Edema, Uveitic Macular Edema
- Trial name
- TIVI (NCT04455399)
- Testing
- Intravitreal injection guide (Malosa), Dual Blade Eyelid Speculum
- Where
- Philippines
- Volunteers
- 200 people
- Sponsor
- Peregrine Eye and Laser Institute
Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a…
- Conditions
- Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization, Age-Related Macular Degeneration
- Trial name
- NCT05662943
- Testing
- Intravitreal aflibercept injection
- Where
- South Korea
- Volunteers
- 135 people
- Sponsor
- Kim's Eye Hospital
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Macular Degeneration
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular…
- Trial name
- NCT00100009
- Testing
- TAC-PF, Triamcinolone Acetonide
- Where
- 23 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Eye Institute (NEI)
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Age Related Macular Degeneration
PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
The primary objective of this study is to assess the ability of the PreView PHP(study device)to detect newly diagnosed non-treated Choroidal Neovascularization (CNV)lesion associate with advanced Age-related Macular Degeneration…
- Trial name
- NCT00358345
- Where
- Israel
- Volunteers
- 347 people
- Sponsor
- Notal Vision Ltd.
Age-related Macular Degeneration
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
This is a pilot, prospective, interventional, case-control study investigating aqueous levels of vascular endothelial growth factor (VEGF) in eyes with AMD-related neovascularization treated with intravitreal bevacizumab at the…
- Trial name
- NCT01350323
- Testing
- Aqueous sample
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- University of Molise
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
MMP-9 Inhibition for Recalcitrant Wet AMD
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world.
- Trial name
- NCT04504123
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Age-Related Maculopathy, Choroidal Neovascularization
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
In this pilot study the researchers will evaluate the safety and efficacy of 50% reduced fluence PDT combination therapy with ranibizumab.
- Trial name
- NCT00473642
- Testing
- Ranibizumab, Verteporfin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Oklahoma State University Center for Health Sciences
Macular Degeneration
A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans
This study is to evaluate the safety, absorption rate and side effects associated with the study drug. Healthy volunteers will be given a single dose of the drug in Part 1.
- Trial name
- NCT01051700
- Testing
- GW786034
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation
Cerebral Stroke
Conjunctival and Retinal Vascularization and Small Vessel Disease
The purpose of the study is to use a simple photography of conjunctival vessels to search for an association between conjunctival vessels abnormalities and the load of small vessel disease as quantified by MRI in patients with…
- Trial name
- EVACORMA (NCT04447599)
- Testing
- photography of conjunctival vessels
- Where
- France
- Volunteers
- 850 people
- Sponsor
- University Hospital, Toulouse
Epiretinal Membrane, Age Related Macular Degeneration
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
- Trial name
- NCT01846351
- Volunteers
- 16 people
- Sponsor
- New England Retina Associates
Age Related Macular Degeneration
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD.
- Trial name
- Foresee Home (NCT01010997)
- Testing
- Foresee Home
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.